Jack O’Meara and Quin Wills hope to develop medicines that eradicate the need for people to have liver transplants. The 29-year-old Athlone native and his South African co-founder have just raised a $30 million series A round of financing for their Oxford-headquartered business, Ochre Bio. Among the VC and angel investors that have backed the firm is one of the best-known Silicon Valley VC firms, Khosla Ventures, which also invested in the Collison brothers’ Stripe. The prevalence of liver disease is rising throughout the West, and it’s one of the top ten causes of death globally. In the US alone,…

Want to continue reading?

Join today with an Annual membership and get full access to The Currency for just €200 (68c per day) or try monthly membership for just €5 for your first month.

Subscribe

Cancel at any time.

Are you already a member? .